Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9608922 | 0.89 | FKBP1A (0.44) | FKBP1AACEACE2KLK5CTSL | |
| SCHEMBL15373369 | 0.89 | POLB (0.44) | FKBP1AACEACE2KLK5CMA1 | |
| SCHEMBL21166676 | 0.89 | CTSL (0.51) | FKBP1AACEKLK5CMA1CTSL | |
| SCHEMBL30406562 | 0.85 | KLK5 (0.46) | ACEKLK5CMA1CTSLELANE | |
| SCHEMBL28853236 | 0.84 | KLK5 (0.53) | FKBP1AACEKLK5CMA1CTSL | |
| SCHEMBL17348390 | 0.84 | KLK5 (0.53) | FKBP1AACEKLK5CMA1CTSL | |
| SCHEMBL28719311 | 0.84 | KLK5 (0.53) | FKBP1AACEKLK5CMA1CTSL | |
| SCHEMBL7311829 | 0.84 | KLK5 (0.53) | FKBP1AACEKLK5CMA1CTSL | |
| SCHEMBL14235323 | 0.84 | KLK5 (0.53) | FKBP1AACEKLK5CMA1CTSL | |
| SCHEMBL12969779 | 0.83 | KCNH2 (0.51) | FKBP1AACEACE2KLK5CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170119901-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2017-05-04 | — | — | US | disclosed |
| WO-2015192123-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119901-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, FAH | FKBP1A 589/4885ACE 197/4885ACE2 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.